Preventive vaccination against human papillomavirus is the new practice in the treatment of cervical cancer. The successful vaccination programs include the use of three vaccines, capable of causing neutralization of antibodies from the virus particles, together with their envelope: the bivalent, quadrivalent and ninevalent HPV vaccines. Following administration of the vaccines, the immune system is being stimulated, producing antibodies to the HPV particles that protect against infection and disease. The safety profile of licensed HPV vaccines based on clinical and post-marketing data is reassuring.
 

Download Full Text - PDF